Spotlight
Money Desk
Obituaries
Classifieds
Families First
News
Weather
Specialists
Sports
Business
Opinion
Consumer
Health
Life
Out & About
Login
Breaking News
U.S. Open scores: Here's the leaderboard for the 124th U.S. Open in Pinehurst
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
Gold
Crude Oil
Local Stocks
WRALTechWire 30
WRALTechWire 30
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Processa Pharmaceuticals Inc
(NQ:
PCSA
)
1.750
+0.100 (+6.06%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jun 14, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Processa Pharmaceuticals Inc
< Previous
1
2
3
Next >
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) to Report on Gastroparesis Results at Annual Digestive Disease Meeting
April 28, 2023
Via
Investor Brand Network
Exposures
Product Safety
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Releases FY 2022 Financials, Corporate Update
March 31, 2023
Via
Investor Brand Network
Exposures
Product Safety
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Schedules Conference Call/Webinar to Review FY 2022 Results, Discuss Corporate Updates
March 23, 2023
Via
Investor Brand Network
Exposures
Product Safety
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Doses First Patient in Key Study of Next-Generation Chemotherapy-Capecitabine
March 17, 2023
Via
Investor Brand Network
Exposures
Product Safety
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Announces Participation in Upcoming Oppenheimer Healthcare Conference
March 07, 2023
Via
Investor Brand Network
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Prioritizes Development of Next Generation Chemotherapies
February 21, 2023
Via
Investor Brand Network
Exposures
Product Safety
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Closes on $6.25M Registered Direct Offering
February 15, 2023
Via
Investor Brand Network
Exposures
Product Safety
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Announces $6.25M Registered Direct Offering
February 10, 2023
Via
Investor Brand Network
Exposures
Product Safety
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) to Present at Biotech Showcase
January 04, 2023
Via
Investor Brand Network
Exposures
Product Safety
InvestorNewsBreaks – Processa Pharmaceuticals Inc.’s (NASDAQ: PCSA) PCS12852 Demonstrates Clinically Meaningful Improvements in Gastroparesis Symptoms
December 14, 2022
Via
Investor Brand Network
Processa Pharmaceuticals Announces PCS12852 Successfully Improves the Clinical Symptoms Associated with Gastroparesis in Phase 2A Trial
December 14, 2022
From
Processa Pharmaceuticals, Inc.
Via
GlobeNewswire
Processa Pharmaceuticals Announces Third Quarter Financial Results and Provides Corporate Update
November 08, 2022
From
Processa Pharmaceuticals, Inc.
Via
GlobeNewswire
InvestorNewsBreaks – Processa Pharmaceuticals Inc.’s (NASDAQ: PCSA) PCS12852 Demonstrates Improved Gastric Emptying in Phase 2A Trial
November 08, 2022
Via
Investor Brand Network
Exposures
Product Safety
PCS12852 Improves Gastric Emptying in Gastroparesis Patients
November 08, 2022
From
Processa Pharmaceuticals, Inc.
Via
GlobeNewswire
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) to Host Conference Call to Discuss Q3 2022 Results, Provide Pipeline Update
November 02, 2022
Via
Investor Brand Network
Exposures
Product Safety
Processa Pharmaceuticals to Host Conference Call to Discuss Third Quarter 2022 Results and Provide Drug Development Update on November 8, 2022 at 4:30 p.m. EST
November 02, 2022
From
Processa Pharmaceuticals, Inc.
Via
GlobeNewswire
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Reports Successful Results from NGC Phase 2B Trial
November 01, 2022
Via
Investor Brand Network
Exposures
Product Safety
Processa Successfully Identifies Next Generation Capecitabine Dosage Regimens for Phase 2B Trial
November 01, 2022
From
Processa Pharmaceuticals, Inc.
Via
GlobeNewswire
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Shares Update on Clinical Programs Enrollment
September 15, 2022
Via
Investor Brand Network
Exposures
COVID-19
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) to Participate at Upcoming Global Investment Conference
September 07, 2022
Via
Investor Brand Network
Exposures
Product Safety
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Names New Key Board Appointments
August 16, 2022
Via
Investor Brand Network
Exposures
Product Safety
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Releases Q2 2022 Results, Corporate Updates
August 12, 2022
Via
Investor Brand Network
Exposures
Product Safety
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Announces Q2 2022 Results Conference Call
August 08, 2022
Via
Investor Brand Network
Exposures
Product Safety
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Launches New Website Focused on Rare Disease
August 04, 2022
Via
Investor Brand Network
Exposures
Product Safety
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) CEO to Present at World Orphan Drug Congress USA
July 12, 2022
Via
Investor Brand Network
Exposures
Product Safety
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Releases Q1 2022 Report, Updates
May 13, 2022
Via
Investor Brand Network
Exposures
Product Safety
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) to Host Conference Call to Discuss Q1 2022 Results, Provide Drug Development Update
May 05, 2022
Via
Investor Brand Network
Exposures
Product Safety
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Administers First Dosage in Amended Phase 1B Study
April 20, 2022
Via
Investor Brand Network
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Enrolls First Patient in PCS12852 Phase 2A Trial
April 05, 2022
Via
Investor Brand Network
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) to Host Conference Call to Discuss Q4 2021 Results, Provide Clinical Pipeline Update
March 23, 2022
Via
Investor Brand Network
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.